Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

[1] Nadler LM(1981)A unique cell surface antigen identifying lymphoid malignancies of B cell origin J Clin Invest 67 134-140

[2] Ritz J(1980)Characterization of a human B lymphocyte-specific antigen J Immunol 125 1678-1685

[3] Hardy R(2018)Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy Front Oncol 8 163-114

[4] Pesando JM(2010)CD20 as a target for therapeutic type I and II monoclonal antibodies Semin Hematol 47 107-497

[5] Schlossman SF(1975)Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495-3154

[6] Stashenko P(1980)Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Res 40 3147-6855

[7] Stashenko P(1984)Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc Natl Acad Sci U S A 81 6851-4603

[8] Pierpont TM(2015)FcRn: The architect behind the immune and non-immune functions of IgG and albumin J Immunol (Baltimore, Md. : 1950) 194 4595-2273

[9] Limper CB(2017)Rituximab in b-cell hematologic malignancies: a review of 20 years of clinical experience Adv Ther 34 2232-473

[10] Richards KL(2005)Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 456-2231

[1] Nadler LM(1981)A unique cell surface antigen identifying lymphoid malignancies of B cell origin J Clin Invest 67 134-140

[2] Ritz J(1980)Characterization of a human B lymphocyte-specific antigen J Immunol 125 1678-1685

[3] Hardy R(2018)Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy Front Oncol 8 163-114

[4] Pesando JM(2010)CD20 as a target for therapeutic type I and II monoclonal antibodies Semin Hematol 47 107-497

[5] Schlossman SF(1975)Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495-3154

[6] Stashenko P(1980)Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Res 40 3147-6855

[7] Stashenko P(1984)Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc Natl Acad Sci U S A 81 6851-4603

[8] Pierpont TM(2015)FcRn: The architect behind the immune and non-immune functions of IgG and albumin J Immunol (Baltimore, Md. : 1950) 194 4595-2273

[9] Limper CB(2017)Rituximab in b-cell hematologic malignancies: a review of 20 years of clinical experience Adv Ther 34 2232-473

[10] Richards KL(2005)Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 456-2231